Kittisak Kaewchalun
- An expert panel of the EU drug regulator, the European Medicines Agency (EMA) on Friday recommended marketing authorization for Pfizer (NYSE:PFE) and BioNTech’s (NASDAQ:BNTX) COVID-19 shot, updated to target the LP.8.1 variant of the virus.
- The positive opinion from the EMA’s Committee for Medicinal Products for Human Use (CHMP) allows the companies to market the monovalent shot for COVID prevention in those aged six months and older in Europe.
- The duo expects to immediately ship the retooled vaccine in all applicable countries, subject to a final decision from the European Commission on the marketing authorization, which is expected “soon,” Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) said.
- The companies added that manufacturing of the LP.8.1-adjusted shot has already begun to ensure there are enough supplies during the upcoming fall and winter season.